Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01642069
First received: July 15, 2012
Last updated: July 27, 2012
Last verified: July 2012

July 15, 2012
July 27, 2012
July 2012
September 2012   (final data collection date for primary outcome measure)
NUP98/JARID1A as a recurrent aberration in pediatric AMKL [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01642069 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL).

OBJECTIVES:

  • To determine whether NUP98/JARID1A expression is a recurrent translocation in NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL).
  • To screen the Children Oncology Group (COG) samples for genetic aberrations in pediatric AMKL.

OUTLINE: Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression profiling by reverse-transcriptase polymerase chain reaction (RT-PCR) and karyotyping or fluorescence in situ hybridization ( FISH). Results are then compared with each patient's outcome data.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Leukemia
  • Genetic: RNA analysis
  • Genetic: fluorescence in situ hybridization
  • Genetic: gene expression analysis
  • Genetic: gene rearrangement analysis
  • Genetic: reverse transcriptase-polymerase chain reaction
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
Not Provided
September 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Cryopreserved specimens of pediatric patients diagnosed with acute megakaryoblastic leukemia

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
up to 30 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01642069
CDR0000736633, COG-AAML12B9
Not Provided
Peter C. Adamson, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Soheil Meshinchi, MD Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP